BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of 2-pyrrolone derivatives as radioprotectors. 2022

Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.

It is known that p53 is an important transcription factor and plays a central role in ionizing radiation (IR)-induced DNA damage responses such as cell cycle arrest, DNA repair and apoptosis. We previously reported that regulating p53 protein is an effective strategy for modulating cell fate by reducing the acute side effects of radiation therapy. Herein, we report on the discovery of STK160830 as a new radioprotector from a chemical library at The University of Tokyo and the design, synthesis and biological evaluation of its derivatives. The radioprotective activity of STK160830 itself and its derivatives that were synthesized in this work was evaluated using a leukemia cell line, MOLT-4 cells as a model of normal cells that express the p53 protein in a structure-activity relationships (SAR) study. The experimental results suggest that a direct relationship exists between the inhibitory effect of these STK160830 derivatives on the expression level of p53 and their radioprotective activity and that the suppression of p53 by STK160830 derivatives contribute to protecting MOLT-4 cells from apoptosis that is induced by exposure to radiation.

UI MeSH Term Description Entries
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D004260 DNA Repair The removal of DNA LESIONS and/or restoration of intact DNA strands without BASE PAIR MISMATCHES, intrastrand or interstrand crosslinks, or discontinuities in the DNA sugar-phosphate backbones. DNA Damage Response
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Design, synthesis and biological evaluation of 2-aminopyridine derivatives as USP7 inhibitors.
December 2022, Bioorganic chemistry,
Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Design, synthesis and biological evaluation of 2-phenylaminopyrimidine derivatives as EGFR inhibitors.
February 2024, Bioorganic & medicinal chemistry letters,
Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Design, Synthesis and Biological Evaluation of Uracil Derivatives as Novel VEGFR-2 Inhibitors.
January 2018, Current pharmaceutical design,
Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.
November 2023, Bioorganic & medicinal chemistry letters,
Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
April 2019, Bioorganic & medicinal chemistry,
Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Design, Synthesis, and Biological Evaluation of 2-Mercaptobenzoxazole Derivatives as Potential Multi-Kinase Inhibitors.
January 2023, Pharmaceuticals (Basel, Switzerland),
Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Design, synthesis and biological evaluation of some 2-azetidinone derivatives as potential antihyperlipidemic agents.
December 2013, Archiv der Pharmazie,
Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.
November 2010, Bioorganic & medicinal chemistry letters,
Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
December 2020, European journal of medicinal chemistry,
Hidetoshi Satoh, and Shintaro Ochi, and Kosuke Mizuno, and Yutaka Saga, and Shohei Ujita, and Miyu Toyoda, and Yuichi Nishiyama, and Kasumi Tada, and Yosuke Matsushita, and Yuichi Deguchi, and Keiji Suzuki, and Yoshimasa Tanaka, and Hiroshi Ueda, and Toshiya Inaba, and Yoshio Hosoi, and Akinori Morita, and Shin Aoki
Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists.
March 2015, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!